SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,121.09 |
| Enterprise Value ($M) | 1,083.95 |
| Book Value ($M) | 388.00 |
| Book Value / Share | 2.71 |
| Price / Book | 2.89 |
| NCAV ($M) | 279.10 |
| NCAV / Share | 1.95 |
| Price / NCAV | 4.02 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.05 |
| Return on Assets (ROA) | -0.04 |
| Return on Equity (ROE) | -0.06 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.11 |
| Current Ratio | 5.60 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 440.46 |
| Assets | 549.36 |
| Liabilities | 161.36 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | |||
| 13D | Tang Capital Management Llc | 5.10 | ||
| 13D/A | ILJIN SNT Co., Ltd. | 5.20 | 4.96 | |
| 13G/A | BlackRock, Inc. | 6.20 | 9.19 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 123,844 | 895,550 | 13.83 | |
| 129,388 | 1,122,850 | 11.52 | |
| 140,710 | 897,871 | 15.67 | |
| 186,316 | 935,924 | 19.91 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ARDX – Ardelyx, Inc. | ATAI – Atai Life Sciences N.V. |
| ATXS – Astria Therapeutics, Inc. | AURA – Aura Biosciences, Inc. |
| AVBP – ArriVent BioPharma, Inc. |